The DNA hypomethylating agent azacytidine, in combination with the BCL-2 inhibitor venetoclax, suppresses Complex II activity by reducing sdhA glutathionylation, which inhibits OXPHOS activity in acute myeloid leukemia stem cells (AML LSCs). This evidence concerns the gene SDHA and acute myeloid leukemia.